A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens. (Q33324419)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18350255 AND SRC:MED&resulttype=core&format=json

4 January 2020

title

A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18350255 AND SRC:MED&resulttype=core&format=json

4 January 2020

0 references

0 references

Doaa A Elsherbiny

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18350255 AND SRC:MED&resulttype=core&format=json

4 January 2020

Sara A Asimus

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18350255 AND SRC:MED&resulttype=core&format=json

4 January 2020

Michael Ashton

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18350255 AND SRC:MED&resulttype=core&format=json

4 January 2020

publication date

19 March 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18350255 AND SRC:MED&resulttype=core&format=json

Journal of Pharmacokinetics and Pharmacodynamics

4 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18350255 AND SRC:MED&resulttype=core&format=json

4 January 2020

volume

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18350255 AND SRC:MED&resulttype=core&format=json

4 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18350255 AND SRC:MED&resulttype=core&format=json

4 January 2020

page(s)

203-217

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18350255 AND SRC:MED&resulttype=core&format=json

Antimalarial drug resistance

4 January 2020

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007/S10928-008-9084-6

Cytochrome P450 enzyme system: genetic polymorphisms and impact on clinical pharmacology

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007/S10928-008-9084-6

Polymorphic metabolism of mephenytoin in man: pharmacokinetic interaction with a co-regulated substrate, mephobarbital

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007/S10928-008-9084-6

Stereospecific analysis of omeprazole supports artemisinin as a potent inducer of CYP2C19

21 January 2018

1 reference

12 December 2020

Artemisinin pharmacokinetics is time-dependent during repeated oral administration in healthy male adults

1 reference

12 December 2020

Enterohepatic circulation: physiological, pharmacokinetic and clinical implications

1 reference

12 December 2020

Antimalarial artemisinin drugs induce cytochrome P450 and MDR1 expression by activation of xenosensors pregnane X receptor and constitutive androstane receptor.

1 reference

12 December 2020

Artemisinin induces omeprazole metabolism in human beings

1 reference

12 December 2020

Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects

1 reference

12 December 2020

Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes

1 reference

12 December 2020

Stereoselective metabolism and disposition of the enantiomers of mephenytoin during chronic oral administration of the racemic drug in man

1 reference

12 December 2020

Retrospective analysis of artemisinin pharmacokinetics: application of a semiphysiological autoinduction model

1 reference

12 December 2020

Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first‐pass metabolism, CYP2D6 genotype and formulation‐dependent bioavailability

1 reference

12 December 2020

A mechanism-based pharmacokinetic-enzyme model for cyclophosphamide autoinduction in breast cancer patients

1 reference

12 December 2020

Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM

1 reference

12 December 2020

Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype

1 reference

12 December 2020

Pharmacokinetic interactions of antimalarial agents

1 reference

12 December 2020

Human N-demethylation of (S)-mephenytoin by cytochrome P450s 2C9 and 2B6.

1 reference

12 December 2020

Stereoselective metabolism and pharmacogenetic control of 5-phenyl-5-ethylhydantoin (nirvanol) in humans.

1 reference

12 December 2020

Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9.

1 reference

12 December 2020

Stereoselective metabolism, pharmacokinetics and biliary elimination of phenylethylhydantoin (Nirvanol) in the dog

1 reference

12 December 2020

Absence of an interaction between artesunate and atovaquone--proguanil

1 reference

12 December 2020

Artemisinin kinetics and dynamics during oral and rectal treatment of uncomplicated malaria

1 reference

12 December 2020

Multiple dose pharmacokinetics of oral artemisinin and comparison of its efficacy with that of oral artesunate in falciparum malaria patients

1 reference

12 December 2020

Pharmacokinetics of artemisinin-type compounds

1 reference

12 December 2020